A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
A phase 3 trial of Penpulimab, Cisplatin, Carboplatin in nasopharyngeal carcinoma, run by Akeso, active and no longer recruiting.
Overview
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma is a phase 3 interventional study registered as NCT04974398 by Akeso, with 296 participants enrolled, started 2021-08-16 and due to reach its primary completion in 2026-02-23. Interventions recorded: Penpulimab, placebo. Conditions listed: Nasopharyngeal Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
Shares Akeso, Gemcitabine, Cisplatin, Carboplatin.
- TrialClinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
Shares Penpulimab, Gemcitabine.
- TrialPhase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Shares Gemcitabine, Cisplatin, Carboplatin.
- Trial9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Shares Gemcitabine, Cisplatin, Carboplatin.
- TrialAK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer
Shares Akeso, Gemcitabine, Cisplatin.
- TrialAK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
Shares Akeso, Cisplatin, Carboplatin.
- TrialStudy of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Shares Gemcitabine, Cisplatin, Carboplatin.
- TrialStudy of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
Shares Gemcitabine, Cisplatin, Carboplatin.